Acting US Food and Drug Administration Commissioner Janet Woodcock expressed openness to sponsors using combinations of endpoints in clinical trials of rare disease drugs to better power studies.
It is “very possible” that sponsors could use predefined combinations of multiple endpoints, Woodcock said in an interview at the...







